Emerging therapies for Duchenne muscular dystrophy
Theodora Markati1, Maryam Oskoui2, Michelle A Farrar3
1MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, UK.
Abstract:
Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional dystrophin in the muscle cells. Major advances have led to the development of gene therapies, tools that induce exon skipping, and other therapeutic approaches, including treatments targeting molecular pathways downstream of the absence of functional dystrophin. However, glucocorticoids remain the only treatment unequivocally shown to slow disease progression, despite the adverse effects associated with their long-term use. Besides glucocorticoids, which are standard care, five compounds have received regulatory approval in some but not all jurisdictions, with further efficacy results being awaited. Several compounds with promising results in early-phase clinical trials have not met their efficacy endpoints in late-phase trials, but the clinical development of many other compounds is ongoing. The current landscape is complicated by the number of compounds in various stages of development, their various mechanisms of action, and their genotype-specific applicability. The difficulties of clinical development that arise from both the rarity and variability of Duchenne muscular dystrophy might be overcome in the future by use of sensitive biomarkers, natural history data, and ameliorated trial designs.
Insights
Glucocorticoids are the only proven treatment for Duchenne muscular dystrophy, despite side effects. Ongoing research explores gene therapies and other compounds, but clinical development faces challenges due to disease rarity and variability.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder characterized by the absence of functional dystrophin in muscle cells.
- Current treatments include glucocorticoids, which slow disease progression but have adverse effects, and several approved compounds with pending efficacy data.
Purpose of the Study:
- To review the current therapeutic landscape for Duchenne muscular dystrophy.
- To highlight the challenges and future directions in clinical development for DMD.
Main Methods:
- Review of current literature on Duchenne muscular dystrophy treatments.
- Analysis of approved therapies, ongoing clinical trials, and emerging therapeutic strategies.
- Discussion of challenges in clinical development, including disease rarity and variability.
Main Results:
- Glucocorticoids remain the only unequivocally effective treatment for slowing DMD progression.
- Several compounds have gained regulatory approval in specific regions, while others have failed to meet endpoints in late-phase trials.
- Numerous compounds targeting various pathways are in ongoing clinical development.
Conclusions:
- The therapeutic landscape for DMD is complex, with multiple compounds and approaches under investigation.
- Overcoming clinical development challenges may involve sensitive biomarkers, natural history data, and improved trial designs.
- Future advancements aim to address the unmet needs in Duchenne muscular dystrophy treatment.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses